33 results about "Podocalyxin" patented technology

Means of conveniently examining nephropathy; and a method of assaying substance(s) in association with nephropathy (for example, podocalyxin and / or nephrin) in the urine to be used in the above means. The above assay method can be provided by releasing proteins in association with nephropathy, which exist on the surface of podocytes, from the cell surface and thus assaying the substances existing on the cell surface and / or free substances contained in the urine.

Methods and kits for detecting cancer and monitoring cancer progression are described. The method involves analyzing a sample containing nucleic acids or proteins from a patient for decreased expression of endoglycan and / or increased expression of podocalyxin.

Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin.

The present invention provides a method for diagnosing and detecting cancer. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in cancer (podocalyxin) and antibodies that bind podocalyxins. The present invention provides that podocalyxins are used as targets for screening agents that modulate podocalyxin activities. Further the present invention provides methods for treating diseases associated with podocalyxin expression.

The disclosure relates to the expression of podocalyxin-like protein (PODXL) on the surface of induced pluripotent stem cells and particularly, although not exclusively, to the use of PODXL as a marker of induced pluripotent stem cells.

The disclosure relates to novel markers of pluripotent stem cells and uses thereof, and particularly, though not exclusively, to antibody molecules based on fragments of mAb84 which bind to undifferentiated pluripotent stem cells via podocalyxin-like protein-1 (PODXL).

The invention provides a colloidal gold kit for detecting a diabetic nephropathy biomarker and a method. The kit comprises a sample pad, a gold standard pad, a nitrocellulose membrane, an absorbent pad and a support pad. The nitrocellulose membrane is provided with a first detection reagent strip, a second detection reagent strip, a third detection reagent strip, a fourth detection reagent strip,and a capture reagent strip successively. The first detection reagent strip coats an anti-IV-type collagen monoclonal antibody; the second detection reagent strip coats an anti-podocalyxin monoclonalantibody; the third detection reagent strip coats an anti-neutropil gelatinase-associated lipocalin monoclonal antibody; the fourth detection reagent strip coats an anti-liver fatty acid binding protein monoclonal antibody; and the capture reagent strip coats a second antibody binding the monoclonal antibody coated on the gold standard pad. According to the invention, with the colloidal gold kit,simultaneous and quantitative detection of various biomarkers of early diabetic nephropathy can be realized; the cost for detecting early diabetic nephropathy is saved; and the detection efficiency isimproved.

The present invention relates to a method of predicting endometrial receptivity of an embryo implantation in a subject, the method comprising determining a level of podocalyxin in endometrial epithelial cells in the subject. The invention also relates to methods of monitoring epithelial cell receptivity and improving epithelial cell receptivity.

Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful.

The invention provides a polymerase chain reaction detection method of urinary podocyte specific messenger ribonucleic acid (mRNA). The method is characterized by being established through the following steps of: collection of urine specimens; total RNA (ribonucleic acid) extraction as well as concentration and purity detection; reverse transcription; design and synthesis of primers; real-time PCR (polymerase chain reaction); preparation of a standard product and manufacture of a standard curve; and real-time PCR of the specimens to be detected and the standard product. The method has the characteristics of rapidness, simplicity and convenience, and can be used for acquiring an excellent quantitative linear correlation coefficient (R2>0.99); simultaneously, the established method is wide in detectable concentration range, podocalyxin and CD2-PA respectively spans 10 orders of magnitude and 8 orders of magnitude, and Ct values corresponding to minimum detectable concentrations of two types of genes respectively reach 35 and 33.2286; and furthermore, the inter-group and inter-batch differences of the high-concentration and light-concentration template Ct values, detected by the method, of the two types of genes are less than 3%, thus indicating that the method is high in stability and good in repeatability. The established method can be used for providing a stable technical platform for rapidly, simply and conveniently detecting the urinary podocyte specific mRNA.

A diabetic nephropathy early detection reagent kit comprising testing reagents. The testing reagents comprise either two or three among a first testing reagent, a second testing reagent, a third testing reagent, and a fourth testing reagent. A solute for the first testing reagent is a first podocalyxin antibody. A solute for the second testing reagent is a first collagen IV antibody. A solute for the third testing reagent is a first liver fatty acid binding protein antibody. A solute for the fourth testing reagent is a first neutrophil gelatinase-associated lipocalin antibody. By having either two or three among podocalyxin, collagen IV, liver fatty acid binding protein, and neutrophil gelatinase-associated lipocalin serving as biomarkers, the diabetic nephropathy early screening reagent kit is capable of providing assistance in determining kidney damages on the basis of an actual testing result, thus providing assistance in distinguishing early-stage diabetic nephropathy.

The present invention relates to a method of estimating the number of urinary podocytes, including detecting podocalyxin in a urinary sediment sample liquid, and more specifically, to a method of estimating the number of urinary podocytes, including the following steps (1) to (3): (1) a step of preparing the urinary sediment sample liquid by separating urinary sediment from urine collected from a test subject and solubilizing podocalyxin in the urinary sediment; (2) a step of calculating a podocalyxin excretion amount in the urinary sediment sample liquid through detection of podocalyxin in the urinary sediment sample liquid; and (3) a step of calculating the number of urinary podocytes by dividing the podocalyxin excretion amount in the urinary sediment sample liquid by a podocalyxin amount per podocyte.

A method of identifying an undifferentiated human embryonic stem cell in a sample which may contain such cells, the method comprising identifying the cell or cells within the sample that express podocalyxin-like protein (PODXL) on their surface. A method of isolating an undifferentiated human embryonic stem cell from a sample containing such cells, the method comprising isolating the cell or cells within the sample that express PODXL on their surface. Typically, the methods use an antibody which binds to PODXL. Undifferentiated human embryonic stem cells isolated by the method may be useful in cell therapy. Also, in particular, compositions of cells differentiated from a human embryonic stem cell but which composition has been depleted of undifferentiated human embryonic stem cells are provided which are useful in cell therapy.

The present invention relates to a method for regulating potency of pluripotent stem cells (PSCs) by modulating expression of podocalyxin-like protein 1 (PODXL) and applications thereof.

Methods and kits for detecting cancer and monitoring cancer progression are described. The method involves analyzing a sample containing nucleic acids or proteins from a patient for decreased expression of endoglycan and / or increased expression of podocalyxin.

A diabetic nephropathy early screening reagent kit comprising testing reagents. The testing reagents comprise a first testing reagent, a second testing reagent, a third testing reagent, and a fourth testing reagent. A solute for the first testing reagent is a first podocalyxin antibody. A solute for the second testing reagent is a first collagen IV antibody. A solute for the third testing reagent is a first liver fatty acid binding protein antibody. A solute for the fourth testing reagent is a first neutrophil gelatinase-associated lipocalin antibody. By having podocalyxin, collagen IV, liver fatty acid binding protein, and neutrophil gelatinase-associated lipocalin serving as biomarkers, the diabetic nephropathy early screening reagent kit is capable of providing assistance in determining kidney damages on the basis of an actual testing result, thus providing assistance in distinguishing early-stage diabetic nephropathy.

Provided is a drug which improves the absorption efficiency of a drug from the mucosal epithelium. This transmucosal administration agent contains, as an active ingredient, an agent compound to which a podocalyxin target molecule is bound.

The purpose of the present invention is to provide a marker that indicates pancreatic cancer and intraductal papillary mucinous tumors, with high sensitivity and specificity. Furthermore, the purposeof the present invention is also to provide a diagnostic kit for pancreatic cancer and intraductal papillary mucinous tumors, which detects this marker, and a method for evaluating metastatic pancreatic cancer and intraductal papillary mucinous tumors, using the marker. This marker of pancreatic cancer and intraductal papillary mucinous tumors is characterized by including one or more proteins, selected from the group consisting of secretoglobin family-1D member 2, and podocalyxin-like protein. Furthermore, this diagnostic kit for pancreatic cancer and intraductal papillary mucinous tumors ischaracterized by including an antibody for one or more proteins selected from the group consisting of secretoglobin family-1D member 2, and podocalyxin-like protein.

Provided is a pharmaceutical agent for enhancing absorption efficiency of a drug through the mucosal epithelial layer. A pharmaceutical agent for transmucosal administration comprises as an active ingredient a drug compound to which a podocalyxin targeting molecule is bound.